SCVMP 26-11-2025

WORKING DOCUMENT No 3

on the implementing act under Article 114(3) of Regulation 2019/6

1. Legal basis

Article 114(3) of Regulation (EU) 2019/6

The Commission shall, by means of implementing acts, at the latest within five years from 28 January 2022, establish a list of substances used in veterinary medicinal products authorised in the Union for use in food-producing terrestrial animal species or substances contained in a medicinal product for human use authorised in the Union in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004, which may be used in food-producing aquatic species in accordance with paragraph 1 of this Article. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 145(2).

The Commission, when adopting those implementing acts, shall take account of the following criteria:

(a) risks to the environment if the food-producing aquatic species are treated with those substances;

(b) impact on animal and public health if the food-producing aquatic species affected cannot receive an antimicrobial listed in accordance with Article 107(6);

(c) availability or lack of availability of other medicinal products, treatments or measures for prevention or treatment of diseases or certain indications in food-producing aquatic species.

2. Preamble

Whereas:

(1) Regulation (EU) 2019/6 lays down rules for use of veterinary medicinal products, including the requirement to use them in accordance with the terms of their marketing authorisations. Where there is no veterinary medicinal product authorised or available in a Member State for an indication concerning a food-producing aquatic species, veterinarians may, in particular to avoid causing unacceptable suffering, under their direct responsibility use medicinal products outside the terms of their marketing authorisations in accordance with the rules laid down in Article 114 of that Regulation.

(2) Article 114(3) of Regulation (EU) 2019/6 provides for the establishment, by means of implementing acts, a list of substances used in veterinary medicinal products authorised in the Union for use in food-producing terrestrial animal species or substances contained in a medicinal product for human use authorised in the Union in accordance with Directive 2001/83/EC of the European Parliament and of the Council ([1]) or Regulation (EC) No 726/2004 of the European Parliament and of the Council ([2]), which may be used in food-producing aquatic species in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6 ("the list").

(3) On the basis of the criteria laid down in Article114(3), the European Medicines Agency ("the Agency") evaluated substances used in veterinary medicinal products authorised in the Union for use in food-producing terrestrial animal species or substances contained in a medicinal product for human use authorised in the Union in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 ([3]),taking into consideration the latest available scientific evidence, Regulation (EC) No 470/2009 ([4]) and Commission Regulation (EU) No 37/2010 ([5]). The Agency also considered information provided from interested parties on the uses and availability of substances in the Union to treat food-producing aquatic species.

(4) The antimicrobials and groups of antimicrobials included in the Annex to Commission Implementing Regulation (EU) 2022/1255 ([6]) are prohibited for any use in animals, including uses

([1]) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67, ELI: http://data.europa.eu/eli/dir/2001/83/oj).

([2]) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1, ELI: http://data.europa.eu/eli/reg/2004/726/oj).

([3]) Scientific advice under Article 114(3) of Regulation (EU) 2019/6 on veterinary medicinal products - List of substances used in veterinary medicinal products authorised in the Union for use in food-producing terrestrial animal species or substances contained in medicinal products for human use authorised in the Union, which may be used in food-producing aquatic species in accordance with Article 114(1) (EMA/CVMP/29892/2024,15 May 2025).

([4]) Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 152, 16.6.2009, p. 11, ELI: http://data.europa.eu/eli/reg/2009/470/oj).

([5]) Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (OJ L 15, 20.1.2010, p. 1, ELI: http://data.europa.eu/eli/reg/2010/37(1)/oj)

([6]) Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022 designating antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans, in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council (OJ L 191, 20.7.2022, p. 58, ELI: http://data.europa.eu/eli/reg_impl/2022/1255/oj).

in accordance with Article 114 of Regulation (EU) 2019/6. Therefore, the Agency did not evaluate those antimicrobials.

(5) The substances having a hormonal or thyrostatic action and beta-agonists included in Annex II to Council Directive 96/22/EC ([7]) are prohibited for use in food-producing aquatic species, including in accordance with Article 114 of Regulation (EU) 2019/6. Therefore, the Agency did not evaluate those substances.

(6) The Agency evaluated all non-immunological substances which could potentially be included in the list. In total, the Agency evaluated 620 non-immunological substances. In line with the Agency's scientific advice, 358 non-immunological substances should be included in the list. Two substances (*Hamamelis virginiana* and ginseng) were recommended by the Agency for inclusion in the list twice, once as a substance contained in homeopathic medicinal products and once as a substance contained in herbal medicinal products. To avoid duplications and uncertainties, only one entry for each of those two substances should be included in the Annex to this regulation. This does not affect the obligations of veterinarians arising from the conditions imposed by Regulation (EU) No 37/2010 when they use homeopathic medicinal products containing those substances in accordance with Article 114(1)(b) or (c).

(7) Immunological medicinal products fall within the scope of Article 114(1) and (2). However, immunological medicinal products are linked to particular pathogens and pathogens are often species-specific. Therefore, the Agency considered, as part of its scientific evaluation, active substances of immunological medicinal products only when the pathogens concerned affect food-producing aquatic species. In line with the Agency's scientific advice, no immunological substances should be included in the list.

(8) There is a need to ensure effective treatment options are available in the Union to address both current and emerging animal health needs in the aquaculture sector. Therefore, the list should be as comprehensive as possible, while guaranteeing high level of environmental protection However, the inclusion of a substance in the list should not be interpreted as a recommendation for its use in food-producing aquatic species.

(9) Taking into consideration the Agency's advice, the use of certain substances in accordance with Article 114(1)(b) and (c) should be subject to conditions and risk mitigation measures aimed at protecting the environment.

(10) Article 107(6), first subparagraph, of Regulation (EU) 2019/6 provides for the possibility for the Commission to establish lists of antimicrobials to be prohibited for use in accordance with Articles 112, 113 and 114 of that Regulation or to be used in accordance with Articles 112, 113 and 114 of that Regulation only subject to certain conditions. This Regulation should apply without prejudice to any measures adopted on that basis regarding the use of antimicrobials in accordance with Article 114 of Regulation (EU) 2019/6.

(11) Article 107(7) of Regulation (EU) 2019/6 allows Member States to further restrict or prohibit the use of antimicrobials in animals on their respective territories if the administration of such antimicrobials to animals is contrary to the implementation of a national policy on prudent use of antimicrobials. This Regulation should therefore apply without prejudice to any such national measures.

([7]) Council Directive 96/22/EC of 29 April 1996 concerning the prohibition on the use in stockfarming of certain substances having a hormonal or thyrostatic action and of ß-agonists, and repealing Directives 81/602/EEC, 88/146/EEC and 88/299/EEC (OJ L 125, 23.5.1996, p. 3–9, ELI: http://data.europa.eu/eli/dir/1996/22/oj)

(12) In order to allow competent authorities, veterinarians, animal keepers and economic operators concerned the necessary time to adapt to the requirements of this Regulation, its application should be deferred.

(13) The list of substances included in the Annex to this Regulation should be kept under continual review in the light of new scientific evidence, as well as the marketing authorisation of new veterinary medicinal products for use in food-producing terrestrial species or medicinal products for human use.

3. Articles

Scope

This Regulation applies to the use of medicinal products in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6.

Rules on the use of substances listed in the Annex

1. The use of a medicinal product containing a substance listed in the Annex shall be subject to the conditions and environmental risk mitigation measures applicable as specified therein.
2. The conditions and environmental risk mitigation measures applicable to each substance listed in the Annex shall be cumulative.
3. The conditions and environmental risk mitigation measures set out in the Annex shall apply without prejudice to the application of:
    a. Article114(6) of Regulation (EU) 2019/6;
    b. any conditions on the use of antimicrobials in accordance with Article 114 of Regulation (EU) 2019/6 adopted on the basis of Article 107(6) of that Regulation;
    c. any measures on the use of antimicrobials adopted in accordance with Article 107(7) of Regulation (EU) 2019/6.

Conditions and environmental risk mitigation measures

1. Condition I: The substance shall be used only when the following conditions are fulfilled:
    a) Therapeutically comparable substances known to be less hazardous to the environment or offering administration methods resulting in a lesser environmental exposure are not available.
    b) If the substance can be used by multiple administration methods, the administration method resulting in lesser environmental exposure and known to achieve a satisfactory therapeutic effect is used.
    c) When possible, treatment takes place in a setup in which effluent containing the substance can be effectively confined, controlled, and treated before being discharged, including but not limited to 'well-boats' as defined in Article (2)(19) of Regulation (EU) 2020/689[8], and:
        i. before discharge in the environment, the substance is removed from or inactivated in the effluent or the solid waste;
        ii. if the removal or inactivation referred to in point i) of this paragraph is not possible,
            – the effluent is directly discharged into a recognised wastewater treatment system, or where direct discharge is not possible, the effluent shall be securely collected, transported, and subsequently discharged into such a system; and
            – the solid waste is disposed of in accordance with local requirements;
        iii. if the removal or inactivation referred to in point i) or the discharge into a recognised wastewater treatment system referred to in point ii) of this paragraph is not possible, before discharge in the environment, the effluent [, when possible ???]is diluted to bring the concentration of the substance below 1 µg/L.

[8] Commission Delegated Regulation (EU) 2020/689 of 17 December 2019 supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards rules for surveillance, eradication programmes, and disease-free status for certain listed and emerging diseases (OJ L 174, 03.6.2020, pp. 211-340, ELI: http://data.europa.eu/eli/reg_del/2020/689/oj)

2. Condition II: When not used in a setup in which effluent containing the substance can be effectively confined, controlled, and treated before being discharged, deltamethrin shall be used only when the following conditions are fulfilled:
   a) Deltamethrin is not used on sea farms located within a distance of 200 meters from where crabs or lobsters are kept.
   b) Deltamethrin is not used where local water currents increase the likelihood of exposure of crabs or lobsters kept in nearby sea farms located at a distance exceeding 200 meters.
   c) When bath treatment is used, it is performed at outgoing tide or during periods with a local outgoing water current.

3. Condition III: The substance shall not be used in combination with beta-lactamase inhibitors.

4. Condition IV: The substance shall be administered in feed only.

5. Condition V: The substance shall be used in individual animals only.

6. Condition VI: The substance shall be used only when contained in homeopathic medicinal products, for which a marketing authorisation has been granted in the Union.

7. Condition VII: The substance shall be administered by injection only.

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from [*OP: please insert the date = 12 months after the date of entry into force of this Regulation*].

4. Annex

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Acetylcysteine	No entry
Acetylmethionine	No entry
Adenosine and its 5'-mono-, 5'- di-and 5' triphosphates	No entry
Adonis vernalis	VI
Aesculus hippocastanum	VI
Agnus castus	VI
Ailanthus altissima	VI
Alanine	No entry
Alarelin	VII
Albendazole	I
Albendazole oxide	I
Alfacalcidol	No entry
Alginic acid	No entry
Allantoin	No entry
Allium cepa	VI
Aloe vera* gel and whole leaf extract of *Aloe vera	No entry
Aloes, Barbados and Capae, their standardised dry extract and preparations thereof	No entry
Aluminium phosphate	No entry
Aluminium potassium sulphate	No entry
Aluminium salicylate, basic	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Ammonium lauryl sulphate	No entry
Amoxicillin	I, III
Ampicillin	I, III
Amprolium	I
***Anisi stellati fructus*, standardised extracts and preparations thereof**	No entry
Apocynum cannabinum	VI
Apramycin	I
Arginine	No entry
***Arnica montana* (*arnicae flos* and *arnicae planta tota*)**	No entry
Artemisia abrotanum	VI
Ascorbic acid	No entry
Asparagine	No entry
Aspartic acid	No entry
Atropa belladonna	VI
Atropine	No entry
Bacitracin	I
Bellis perennis	VI
Benzocaine	I
Benzylpenicillin	I
Betaine	No entry
Biotin	No entry
Bromelain	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Bronopol	I
Brotizolam	No entry
Bupivacaine	No entry
Buserelin	VII
Butafosfan	No entry
Butylscopolaminium bromide	No entry
Calcium ascorbate	No entry
Calcium borogluconate	No entry
Calcium chloride	No entry
Calcium citrate	No entry
Calcium glucoheptonate	No entry
Calcium gluconate	No entry
Calcium glucono glucoheptonate	No entry
Calcium glycerophosphate	No entry
Calcium hypophosphite	No entry
Calcium lactate	No entry
Calcium pantothenate	No entry
Calcium phosphate	No entry
Calcium propionate	No entry
Calendula officinalis	VI
Calendulae flos	No entry
Camphora	VI
Capsici fructus acer	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Carazolol	No entry
Carbomer	No entry
Carbon dioxide	No entry
Cardiospermum halicacabum	VI
Carlinae radix	No entry
Carnitine	No entry
Carprofen	No entry
Carrageenan	No entry
Caryophilli aetheroleum **(clove oil)**	No entry
Cefacetrile	III
Cefalexin	III
Cefalonium	I, III
Cefapirin	III
Cefazolin	III
[Cefoperazone[1]	I, III, V
Cefquinome[1]	I, III, V
Ceftiofur[1]	I, III, V]
Centellae asiaticae extractum	No entry
Chlortetracycline	I
Choline	No entry
Chondrogenic induced equine peripheral blood-derived mesenchymal stem cells	No entry

[1] In their Scientific Advice under Article 107(6), the Agency recommended this substance 'Not to be used in food-producing aquaculture'

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Cimicifugae racemosae rhizoma	No entry
Cinchonae cortex**, standardised extracts and preparations thereof**	No entry
Citrulline	No entry
Clodronic acid (in the form of disodium salt)	No entry
Cloprostenol	VII
Cloxacillin	No entry
Cobalt gluconate	No entry
Condurango cortex**, standardised extracts and preparations thereof**	No entry
Convallaria majalis	VI
Copper methionate	No entry
Copper sulphate	I
Crataegus	VI
Curcumin	No entry
Cytidine and its 5'-mono-, 5'-di- and 5'-triphosphates	No entry
[Danofloxacin	I[2]]
Decoquinate	I, IV
Deltamethrin	I, II
Dembrexine	No entry

[2] In their Scientific Advice under Article 107(6), the Agency recommended

- when a human medicinal product containing this substance is used, then that use should be restricted to individual animals only;
- when a veterinary medicinal product containing this substance is used via a route of administration which is outside the terms its SPC, then that use should be restricted to individual animals only.

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Denaverine hydrochloride	No entry
Detomidine	No entry
Dexamethasone	VII
Dexpanthenol	No entry
Dicloxacillin	No entry
[Difloxacin[3]	I]
Dihydrostreptomycin	No entry
Dimethicone	No entry
Dinoprost tromethamine	VII
Dinoprostone	VII
Diprophylline	No entry
Doxapram	No entry
Doxycycline	I
D-Phenylalanine (6) luteinising-hormone releasing hormone	VII
Echinacea	VI
Echinacea purpurea	No entry
Enilconazole	I
[Enrofloxacin[2]	I]

[3] In their Scientific Advice under Article 107(6), the Agency recommended

- when a human medicinal product containing this substance is used, then that use should be restricted to individual animals only;
- when a veterinary medicinal product containing this substance is used via a route of administration which is outside the terms its SPC, then that use should be restricted to individual animals only.

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Epinephrine	VII
Equine umbilical cord-derived mesenchymal stem cells	No entry
Ergometrine maleate	No entry
Erythromycin	I
Etamsylate	No entry
Eucalyptus globulus	VI
Euphrasia officinalis	VI
Fenbendazole	I
Fenpipramide hydrochloride	No entry
Ferrous gluconate	No entry
Florfenicol	I
Flubendazole	I
[Flumequine[4]	I]
Follicle stimulating hormone (natural FSH from all species and their synthetic analogues)	VII
Formaldehyde	I
Formosulfathiazole	I
Frangulae cortex**, standardised extracts and preparations thereof**	No entry
Gamithromycin	No entry

[4] In their Scientific Advice under Article 107(6), the Agency recommended

- when a human medicinal product containing this substance is used, then that use should be restricted to individual animals only;
- when a veterinary medicinal product containing this substance is used via a route of administration which is outside the terms its SPC, then that use should be restricted to individual animals only.

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Gentamicin	I
***Gentianae radix*, standardised extracts and preparations thereof**	No entry
Ginkgo biloba	VI
***Ginseng*, standardised extracts and preparations thereof**	No entry
Glutamic acid	No entry
Glutamine	No entry
Glycerol	No entry
Glycine	No entry
Gonadorelin	VII
Hamamelis virginiana	No entry
Harpagophytum procumbens	VI
Harunga madagascariensis	VI
Helium	No entry
Heparin and its salts	No entry
Heptaminol	No entry
Hesperidin	No entry
Hesperidin methyl chalcone	No entry
Hexetidine	No entry
Histidine	No entry
Human chorionic gonadotropin (HCG)	VII

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Humic acids and their sodium salts	No entry
Hydrocortisone	VII
Hydrogen peroxide	I
Hydroxypropyl methyl cellulose	No entry
Hyperici oleum	No entry
Hypericum perforatum	VI
Imidocarb	I
Inosine	No entry
Inositol	No entry
Iron dextran	No entry
Iron sulphate	No entry
Isoeugenol	I
Isoleucine	No entry
Isopropanol	No entry
Kanamycin	No entry
Karaya gum	No entry
Ketamine	VII
Ketanserin tartrate	No entry
Lactitol	No entry
Lanolin	No entry
Lecirelin	VII
Lecithins	No entry
Leucine	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Levamisole	I
Lidocaine	No entry
Lincomycin	I
Lini oleum	No entry
Lobaria pulmonaria	VI
Luteinising hormone (natural LH from all species and their synthetic analogues)	VII
Lycopene	No entry
Lysine	No entry
Magnesium acetate	No entry
Magnesium aspartate	No entry
Magnesium carbonate	No entry
Magnesium chloride	No entry
Magnesium citrate	No entry
Magnesium gluconate	No entry
Magnesium glycerophosphate	No entry
Magnesium hydroxide	No entry
Magnesium hypophosphite	No entry
Magnesium orotate	No entry
Magnesium phosphate	No entry
Magnesium sulfate	No entry
Manganese gluconate	No entry
Manganese glycerophosphate	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Mannitol	No entry
[Marbofloxacin[5]	I]
Mebendazole	I
Medicago sativa extractum	No entry
Medroxyprogesterone acetate	VII
Mepivacaine	No entry
Monensin	I
Monosodium glutamate	No entry
Nafcillin	No entry
Natamycin	No entry
Neomycin	I
Nicoboxil	No entry
Nitrogen	No entry
Nitrous oxide	No entry
Nonivamide	No entry
Novobiocin	I
Okoubaka aubrevillei	VI
Ornithine	No entry
Orotic acid	No entry

[5] In their Scientific Advice under Article 107(6), the Agency recommended

- when a human medicinal product containing this substance is used, then that use should be restricted to individual animals only;
- when a veterinary medicinal product containing this substance is used via a route of administration which is outside the terms its SPC, then that use should be restricted to individual animals only.

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Oxacillin	No entry
Oxfendazole	I
[Oxolinic acid[6]	I]
Oxygen	No entry
Oxytetracycline	I
Oxytocin	VII
Pancreatin	No entry
Papain	No entry
Papaverine	No entry
Parconazole	No entry
Paromomycin	No entry
Patent Blue V	No entry
Penethamate	No entry
Pepsin	No entry
Phenoxymethylpenicillin	No entry
Phenylalanine	No entry
Phthalylsulfathiazole	I
Phytolacca americana	VI
Pirlimycin	No entry

[6] In their Scientific Advice under Article 107(6), the Agency recommended

- when a human medicinal product containing this substance is used, then that use should be restricted to individual animals only;
- when a veterinary medicinal product containing this substance is used via a route of administration which is outside the terms its SPC, then that use should be restricted to individual animals only.

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Poloxamer	No entry
Polyoxyethylene sorbitan monopalmitate (polysorbate 40)	No entry
Polyoxyethylene sorbitan monostearate (polysorbate 60)	No entry
Polysulfated glycosaminoglycan	No entry
Polyvinylpolypyrrolidone	No entry
Potassium acetate	No entry
Potassium citrates	No entry
Potassium DL-aspartate	No entry
Potassium gluconate	No entry
Potassium glycerophosphate	No entry
Potassium malate	No entry
Potassium phosphates	No entry
Potassium tartrates	No entry
Praziquantel	I
Pregnant mare serum gonadotrophin (equine chorionic gonadotropin, PMSG)	VII
Probiotic components including bacteria and yeasts	No entry
Procaine	No entry
Progesterone	VII
Proline	No entry
Propylene glycol	No entry
Prunus laurocerasus	VI

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Quercus cortex	No entry
***Quillaia* saponins**	No entry
R-Cloprostenol	VII
Rifaximin	I
Romifidine	No entry
Ruscus aculeatus	No entry
Sambuci flos	No entry
Selenicereus grandiflorus	VI
Serenoa repens	VI
Serine	No entry
Silybum marianum	VI
Sodium carbonates	No entry
Sodium chloride	No entry
Sodium citrates	No entry
Sodium cromoglycate	No entry
Sodium gluconate	No entry
Sodium glycerophosphate	No entry
Sodium hypophosphite	No entry
Sodium phosphates	No entry
Sodium propionate	No entry
Sodium thiosulfate	No entry
Solidago virgaurea	VI
Sorbitan sesquioleate	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Sorbitols	No entry
Spectinomycin	I
Spiramycin	I
Streptomycin	No entry
Other substances used in homeopathic veterinary medicinal products for which a marketing authorisation has been granted in the Union	VI
Sulfacetamide	I
Sulfachlorpyridazine	I
Sulfadiazine	I
Sulfadimethoxine	I
Sulfadimidine	I
Sulfadoxine	I
Sulfafurazole	I
Sulfaguanidine	I
Sulfamerazine	I
Sulfamerazine	I
Sulfamethizole	I
Sulfamethizole	I
Sulfamethoxazole	I
Sulfamethoxypyridazine	I
Sulfamonomethoxine	I
Sulfanilamide	I

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Sulfapyridine	I
Sulfaquinoxaline	I
Sulfathiazole	I
Sulfogaiacol	No entry
Symphyti radix	No entry
Syzygium cumini	VI
Tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells	No entry
Terebinthinae laricina	No entry
Terpin hydrate	No entry
Tetracaine	No entry
Tetracycline	I
Thiamphenicol	I
Thiopental sodium	No entry
Threonine	No entry
Thuja occidentalis	VI
Tiamulin	I
Tildipirosin	No entry
Tiliae flos	No entry
Tilmicosin	I
Tiludronic acid (in the form of disodium salt)	No entry
Toldimfos	No entry
Tolfenamic acid	No entry

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Toltrazuril	I
Tosylchloramide sodium	I
Trichlormethiazide	No entry
Trimagnesium dicitrate	No entry
Trimethoprim	I
Trimethylphloroglucinol	No entry
Triptorelin acetate	VII
Tryptophan	No entry
Tulathromycin	I
Turnera diffusa	VI
Tylosin	I
Tylvalosin	No entry
Tyrosine	No entry
Urginea maritima	VI
Uridine and its 5'-mono-5'-di- and 5'-triphosphates	No entry
Urticae herba	No entry
Valine	No entry
Valnemulin	I
Vedaprofen	No entry
Vetrabutine hydrochloride	No entry
Vincamine	No entry
Virola sebifera	VI

Substance	Conditions and environmental risk mitigation measures for the use in accordance with Article 114(1)(b) and (c) of Regulation (EU) 2019/6
Viscum album	VI
Vitamin B1 (thiamine)	No entry
Vitamin B12	No entry
Vitamin B2	No entry
Vitamin B5	No entry
Xylitol	No entry